Imbio, LLC, a medical imaging software company, has closed on $1.5 million in Series A financing. Existing investor Invenshure, LLC, led the round with additional funding from several angel investors. The proceeds will support the commercialization of Imbio’s proprietary Parametric Response Mapping (PRM) technology used to detect, characterize and quantify abnormal tissue in computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images.
November 28, 2016 – CHICAGO–(BUSINESS WIRE)–NTT DATA Services, formerly Dell Services, today announced its partnership with Imbio, which will provide algorithms for lung analytics. The algorithms are designed to further enhance automated tools for assisting radiology in identifying and quantifying disease present in existing and new imaging studies. The algorithms from Imbio provide for fully-automated quantification and visualization of lung structure, which is key to personalized diagnosis, surgical planning and therapy response monitoring. The Unified Clinical Archive (UCA) services from NTT DATA Services include a universal imaging analytics solution that supports machine vision and neural networks to more rapidly identify the extent of disease and accelerate the identification of incidental findings for early detection of potential chronic disease.
MINNEAPOLIS, March 21, 2016 /PRNewswire/ — Imbio, a leader in fully automated, biomarker-based solutions for quantitative Lung imaging, and GE Healthcare are pleased to announce a collaboration to make Imbio’s Lung Density Analysis™, a volumetric imaging solution for Lung CT, one of the first software applications to be available in the GE Health Cloud.
MINNEAPOLIS, Minnesota – The Minnesota High Tech Association (MHTA) has named Imbio as a finalist in the Healthcare – Small & Growing category for the 2015 Tekne Awards, which will be held at the Minneapolis Convention Center on Thursday, Nov. 18. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership.
MINNEAPOLIS, Minnesota—Imbio, LLC, a diagnostic medical imaging software company, announced today that the company has exclusively licensed technology for evaluation of pulmonary embolisms developed by joint research between Massachusetts Institute of Technology (MIT), Universidad Politécnica de Madrid (UPM), and Brigham and Women’s Hospital (BWH).